Jeff Yass’s Axsome Therapeutics AXSM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $21.5M | Buy |
87,815
+40,617
| +86% | +$8.81M | ﹤0.01% | 2388 |
|
|
2026
Q1 | $7.98M | Buy |
47,198
+17,357
| +58% | +$3M | ﹤0.01% | 3467 |
|
|
2025
Q4 | $5.45M | Sell |
29,841
-20,405
| -41% | -$2.85M | ﹤0.01% | 3885 |
|
|
2025
Q3 | $6.1M | Sell |
50,246
-55,775
| -53% | -$6.28M | ﹤0.01% | 3776 |
|
|
2025
Q2 | $11.1M | Buy |
106,021
+54,295
| +105% | +$5.75M | ﹤0.01% | 2695 |
|
|
2025
Q1 | $6.03M | Buy |
51,726
+32,956
| +176% | +$3.75M | ﹤0.01% | 3302 |
|
|
2024
Q4 | $1.59M | Buy |
+18,770
| New | +$1.73M | ﹤0.01% | 5818 |
|
|
2024
Q3 | – | Sell |
-25,616
| Closed | -$2.24M | – | 11951 |
|
|
2024
Q2 | $2.06M | Sell |
25,616
-13,705
| -35% | -$1.01M | ﹤0.01% | 5039 |
|
|
2024
Q1 | $3.14M | Buy |
39,321
+26,558
| +208% | +$2.23M | ﹤0.01% | 4440 |
|
|
2023
Q4 | $1.02M | Buy |
12,763
+9,453
| +286% | +$632K | ﹤0.01% | 6959 |
|
|
2023
Q3 | $231K | Sell |
3,310
-7,500
| -69% | -$561K | ﹤0.01% | 9905 |
|
|
2023
Q2 | $777K | Sell |
10,810
-22,368
| -67% | -$1.65M | ﹤0.01% | 7270 |
|
|
2023
Q1 | $2.05M | Buy |
33,178
+30,532
| +1,154% | +$2.01M | ﹤0.01% | 5085 |
|
|
2022
Q4 | $204K | Sell |
2,646
-84,926
| -97% | -$5.08M | ﹤0.01% | 10074 |
|
|
2022
Q3 | $3.91M | Buy |
87,572
+37,768
| +76% | +$1.89M | ﹤0.01% | 3554 |
|
|
2022
Q2 | $1.91M | Buy |
+49,804
| New | +$1.58M | ﹤0.01% | 5003 |
|
|
2022
Q1 | – | Sell |
-116,144
| Closed | -$3.6M | – | 12957 |
|
|
2021
Q4 | $4.39M | Sell |
116,144
-51,648
| -31% | -$1.9M | ﹤0.01% | 3973 |
|
|
2021
Q3 | $5.53M | Buy |
167,792
+108,675
| +184% | +$4.24M | ﹤0.01% | 3767 |
|
|
2021
Q2 | $3.99M | Sell |
59,117
-15,850
| -21% | -$951K | ﹤0.01% | 4443 |
|
|
2021
Q1 | $4.25M | Sell |
74,967
-13,921
| -16% | -$979K | ﹤0.01% | 4222 |
|
|
2020
Q4 | $7.24M | Sell |
88,888
-28,678
| -24% | -$2.14M | ﹤0.01% | 2903 |
|
|
2020
Q3 | $8.38M | Sell |
117,566
-17,194
| -13% | -$1.34M | ﹤0.01% | 2402 |
|
|
2020
Q2 | $11.1M | Sell |
134,760
-35,462
| -21% | -$2.73M | ﹤0.01% | 2024 |
|
|
2020
Q1 | $10M | Sell |
170,222
-333,132
| -66% | -$27.1M | ﹤0.01% | 1740 |
|
|
2019
Q4 | $52M | Buy |
503,354
+255,210
| +103% | +$10.3M | 0.02% | 787 |
|
|
2019
Q3 | $5.02M | Buy |
248,144
+204,184
| +464% | +$5.25M | ﹤0.01% | 2719 |
|
|
2019
Q2 | $1.13M | Sell |
43,960
-43,386
| -50% | -$870K | ﹤0.01% | 5373 |
|
|
2019
Q1 | $1.24M | Buy |
87,346
+74,062
| +558% | +$688K | ﹤0.01% | 4591 |
|
|
2018
Q4 | $37K | Buy |
+13,284
| New | +$43.7K | ﹤0.01% | 8565 |
|
|
2018
Q2 | – | Sell |
-17,318
| Closed | -$53.7K | – | 9584 |
|
|
2018
Q1 | $42K | Sell |
17,318
-51,477
| -75% | -$154K | ﹤0.01% | 9004 |
|
|
2017
Q4 | $385K | Buy |
+68,795
| New | +$347K | ﹤0.01% | 7130 |
|
|
2017
Q3 | – | Sell |
-34,238
| Closed | -$188K | – | 8790 |
|
|
2017
Q2 | $188K | Buy |
+34,238
| New | +$143K | ﹤0.01% | 8343 |
|
|
2016
Q2 | – | Sell |
-13,302
| Closed | -$114K | – | 8522 |
|
|
2016
Q1 | $114K | Buy |
+13,302
| New | +$122K | ﹤0.01% | 8370 |
|
Other funds holding AXSM
DTC
Jeff Yass's AXSM Position: Q2 2026 in Review
Jeff Yass increased its Axsome Therapeutics (AXSM) stake by 86% in Q2 2026, buying an estimated $8.81M and bringing the position to 87,815 shares worth $21.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2388.
Jeff Yass first reported a position in AXSM in Q1 2016 and has held it in 33 quarters since. The position peaked at $52M in Q4 2019. 503 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.
- Jeff Yass held 87,815 shares of Axsome Therapeutics worth $21.5M as of Q2 2026.
- Jeff Yass bought 40,617 Axsome Therapeutics shares in Q2 2026, an estimated $8.81M.
- Axsome Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #2388 holding.
- Jeff Yass first reported a position in Axsome Therapeutics in Q1 2016 and has held it in 33 quarters since.
- Jeff Yass's Axsome Therapeutics position peaked at $52M in Q4 2019.
- 503 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.
Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.